Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
暂无分享,去创建一个
Hartwig Huland | Markus Graefen | Thorsten Schlomm | Ronald Simon | Guido Sauter | Lars Budäus | G. Sauter | T. Schlomm | T. Clauditz | C. Wittmer | R. Simon | F. Jacobsen | W. Wilczak | S. Minner | M. Tsourlakis | M. Graefen | G. Salomon | L. Budäus | H. Huland | D. Höflmayer | M. Kluth | C. Hube-Magg | J. Izbicki | F. Büscheck | A. Luebke | A. Hinsch | I. Thederan | Georg Salomon | Cornelia Schroeder | Frank Jacobsen | Jakob R. Izbicki | Sarah Minner | Juliane Kraft | Cornelia Schroeder | Claudia Hube-Magg | Martina Kluth | Dagmar S. Lang | Till S. Clauditz | Andreas M. Luebke | Andrea Hinsch | Waldemar Wilczak | Corinna Wittmer | Franziska Büscheck | Doris Höflmayer | Maria Christina Tsourlakis | Imke Thederan | Nathaniel Melling | N. Melling | D. Lang | Imke Thederan | J. Kraft | Corinna Wittmer
[1] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[2] G. Ayala,et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] E. Chien,et al. Androgen-regulated cervical ripening: a structural, biomechanical, and molecular analysis. , 2008, American journal of obstetrics and gynecology.
[4] A. Piga,et al. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma , 2013, Tumor Biology.
[5] W. Zimmer,et al. Synergistic immunologic targets for the treatment of prostate cancer , 2016, Experimental biology and medicine.
[6] Jin Woo Kim,et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.
[7] Ian G. Mills,et al. The role of glycans in the development and progression of prostate cancer , 2016, Nature Reviews Urology.
[8] G. Petrovski,et al. The cytoprotective effect of biglycan core protein involves Toll-like receptor 4 signaling in cardiomyocytes. , 2016, Journal of molecular and cellular cardiology.
[9] H. Xu,et al. Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.
[10] Xiaohu Gu,et al. Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer , 2015, Tumor Biology.
[11] M. Kahn,et al. The Wnt signaling pathway in cancer. , 2016, Critical reviews in oncology/hematology.
[12] R. Iozzo,et al. Biological interplay between proteoglycans and their innate immune receptors in inflammation , 2013, The FEBS journal.
[13] Rikang Wang,et al. TGF-β stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle , 2011, Growth factors.
[14] M. Kurosaka,et al. PTEN regulates matrix synthesis in adult human chondrocytes under oxidative stress , 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[15] Marian F Young,et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.
[16] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[17] C. Eng,et al. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. , 2012, Human molecular genetics.
[18] B. Seliger,et al. HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties* , 2012, The Journal of Biological Chemistry.
[19] T. Zeng,et al. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. , 2013, International journal of clinical and experimental pathology.
[20] J. Korbel,et al. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.
[21] Roger R. Gomis,et al. TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.
[22] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[23] C. Plass,et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.
[24] D. Watson,et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.
[25] Tim Beißbarth,et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.
[26] J. Fischer,et al. Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts , 2009, Basic Research in Cardiology.
[27] J. Fischer,et al. Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer , 2013, PloS one.
[28] Yiqing Zhao,et al. Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis , 2016, Oncotarget.
[29] Ning Yang,et al. Expression and significance of biglycan in endometrial cancer , 2014, Archives of Gynecology and Obstetrics.
[30] Hua-mei Tang,et al. Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer , 2011, Experimental biology and medicine.
[31] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[32] J. Fischer,et al. Interindividual Transcriptional Regulation of the Human biglycan Gene Involves Three Common Molecular Haplotypes , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[33] Bingya Liu,et al. Biglycan enhances gastric cancer invasion by activating FAK signaling pathway , 2014, Oncotarget.
[34] N. D. de Araújo,et al. Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[35] Ronald Simon,et al. Recipient block TMA technique. , 2010, Methods in molecular biology.
[36] K. Rungsrisuriyachai,et al. Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells. , 2014, Journal of pharmaceutical sciences and pharmacology.
[37] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[38] S. Iacob,et al. Biglycan regulates the expression of EGF receptors through EGF signaling pathways in human articular chondrocytes , 2010, Connective tissue research.
[39] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[40] Eleni Bazigou,et al. Cell signaling and cancer , 2007, Genome Biology.
[41] Li-li Zhang,et al. Biglycan enhances the ability of migration and invasion in endometrial cancer , 2016, Archives of Gynecology and Obstetrics.
[42] E. Reddy,et al. Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers. , 2014, Journal of pharmaceutical sciences and pharmacology.
[43] H. Huland,et al. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. , 1997, The Journal of urology.
[44] A J Bailey,et al. Changes in collagen metabolism in prostate cancer: a host response that may alter progression. , 2001, The Journal of urology.
[45] T. Gress,et al. Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. , 2001, Gastroenterology.
[46] L. Hood,et al. Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. , 2009, Omics : a journal of integrative biology.
[47] G. Sauter,et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.
[48] M. Brawer,et al. Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.
[49] Marian F Young,et al. Biglycan , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[50] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[51] M. Young,et al. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors , 2004, Journal of cellular biochemistry.
[52] S. Kurtz,et al. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.
[53] Yuehua Gong,et al. Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers , 2012, Clinical and Experimental Medicine.
[54] Bruce J Trock,et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.
[55] Junqing Ma,et al. Biglycan mediates suture expansion osteogenesis via potentiation of Wnt/β-catenin signaling. , 2015, Journal of biomechanics.
[56] A. Jemal,et al. Global Cancer Statistics , 2011 .
[57] Yuxin Yin,et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity , 2015, Nature Immunology.
[58] R. Iozzo,et al. Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction* , 2008, Journal of Biological Chemistry.
[59] P. Little,et al. Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. , 2005, Endocrinology.
[60] A. Haese*,et al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.
[61] E. Ruoslahti,et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. , 1994, The Biochemical journal.
[62] Y. Ohba,et al. Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan , 2016, Scientific Reports.
[63] H. He,et al. SOX9 drives WNT pathway activation in prostate cancer. , 2016, The Journal of clinical investigation.